BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Ilex Medical Ltd Signs Africa Distribution Deal With Novartis AG (NVS)


10/5/2012 9:03:42 AM

Oct 04, 2012 (Menafn - Globes - McClatchy-Tribune Information Services via COMTEX) --Ilex Medical Ltd. (tase:ILX) has signed an exclusive distribution agreement to distribute blood test kits for Novartis AG NVS(swx:NOVZ) unit Novartis Vaccines and Diagnostics SAS in Africa. Ilex subsidiary Ilex Biotech Ltd. already distributes the kits in South Africa; the new agreement expands the distribution to 16 additional Sub-Saharan countries.

Ilex estimates the market potential in these countries at 50 million a year, based on 2.5 million blood donations a year. It notes that there are one million blood donations a year in South Africa, and 320,000 donations a year in Israel.

The company's sales in South Africa totaled NIS 95 million in 2011, out of its total revenue of NIS 250 million. Sales of Novartis's blood test kits to the South African National Blood Service account for 14 percent of the company's revenue. The segment is important for Ilex, even though African countries are not usually considered important revenue sources for life sciences companies.

Ilex's primary market is Israel, and it is expanding to Russia and other countries.

Two weeks ago, Ilex announced that it plans to merge its operations with Medtechnica Ltd. (tase:MEDI), a distributor of medical equipment in Israel, which it acquired in March 2011 for NIS 260 million. Since the acquisition, Medtechnica's market cap has fallen to NIS 146 million, 65 percent of the acquisition price, reflecting a paper loss of NIS 170 million for Ilex. Ilex's share price has fallen 30 percent over the same period, and its current market cap is NIS 120 million.


Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->